Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-2100 in Advanced or Metastatic Clear-cell Renal Cell Carcinoma
NCT06245915Phase 2Active, not recruiting
- Sponsor
- Arsenal Biosciences, Inc.
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AB-2100 in clear cell renal cell carcinoma (ccRCC), sponsored by Arsenal Biosciences, Inc.. Started Feb 2024; status: active, not recruiting.
02
Drugs
AB-2100
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06245915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245915.